Chairpersons :

Neha Choudhary, Kajal Shah, Raj Nagarkar

Reviewer :

Christopher Twelves

1. Development of a Ki-67 based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer Author: Rodrigo Goncalves Citation: Breast Cancer Res Treat. 2017 Sep;165(2):355-364

2. Peri-operative aromatase inhibitor treatment in determining or predicting long-term outcome in early breast cancer - The poetic trial (CRUK/07/015) Author: John Robertson Citation: SABCS Abstract GS1-03

3. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor positive breast cancer treated with 5 years of endocrine therapy Author: Ivana Sestak Citation: SABCS Abstract GS6-01

4. Copy number aberration analysis to predict response to neoadjuvant Anti-HER2 therapy: results from the Neo Altto phase III trial Author: Sotiriou C. Citation: SABCS Abstract GS1-04

5. CDK4/6 inhibition triggers anti-tumour immunity Author: Goel S. Citation: Nature. 2017 Aug 24;548(7668):471-475

6. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor–positive, node-positive early breast cancer: Final results of the randomized phase III Femara versusn Anastrozole Clinical Evaluation (FACE) trial Author: Ian Smith Citation: J Clin Oncol. 2017 Apr 1;35(10):1041-1048

7. 20 year risks of breast cancer recurrence after stopping endocrine therapy at 5 years Author: Pan H. Citation: N Engl J Med. 2017 Nov 9;377(19):1836-1846 

8. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor–associated arthralgias in early-stage breast cancer: SWOG S1202 Author: N. Lynn Henry Citation: J Clin Oncol. 2018 Feb 1;36(4):326-332

9. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): An open-label, single-group, multicentre, phase 2 trial Author: Llombart-Cussac A. Citation: Lancet Oncol. 2017 Apr;18(4):545-554

10. Phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer brain metastases Author: Rachel A. Freedman Citation: Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 1005-1005 

11. The endopredict score predicts residual cancer burden to neoadjuvant chemotherapy and to neo-endocrine therapy in HR+/HER2 - breast cancer patients from ABCSG 34 Author: Dubsky PC Citation: SABCS Abstract GS6-04

12. Randomized blinded sham and waitlist controlled trial of accupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (SWOG 1200) Author: Dawn L. Hershman Citation: SABCS Abstract GS4-04

13. Phase IB/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastzumab-resistant her2-positive advanced breast cancer: Results from the PANACEAstudy (IBCSG 45-13/BIG 4-13/KEYNOTE-014) Author: Sherene Loi Citation: San Antonio, TX. Abstract GS2-06 

14. NSABP B-47 (NRG oncology) phase III RCT comparing adjuvant chemotherapy with AC - weekly paclitaxel or TC x 6 with or without trastuzumab for 1 year in high-risk, invasive breast cancer negative for HER2 by ISH and with IHC 1+ or 2+ (HER2 - low IBC) Author: Louis Fehrenbacher

15. Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the success a study Author: Wolfgang Janni Citation: SABCS Abstract GS1-06

16. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor–positive early breast cancer Author: Laenkholm AV Citation: J Clin Oncol. 2018 Jan 25:JCO2017746586